Camden, NJ (PRWEB) August 31, 2016
Lourdes Health System recently announced the addition of a fellowship-trained, subspecialty neurologist, G. Peter Gliebus, M.D., to its multi-specialty center located on Brace Road, Cherry Hill, NJ. Dr. Gliebus specializes in Alzheimer’s disease, cognitive disorders, dementia and concussions.
Dr. Gliebus is part of Drexel Neurosciences Institute (DNI) where he is an assistant professor of neurology and serves as director of Drexel’s Cognitive Disorders Center. Lourdes and DNI have entered into an agreement whereby a group of subspecialty neurologists will establish regular office hours at Lourdes’ convenient outpatient location. Dr. Gliebus will immediately begin to see patients, and he will be joined very shortly by subspecialists in Parkinson’s disease/movement disorders, epilepsy, comprehensive pain management and neuropsychology. Prior to joining Drexel, Dr. Gliebus was director of the Alzheimer’s disease and Cognitive Disorders Center at Capital Health System in Trenton, NJ.
Dr. Gliebus completed a behavioral and cognitive neurology fellowship at Northwestern University’s Cognitive Neurology and Alzheimer’s Disease Center. He performed his neurology residency at Hahnemann University Hospital/Drexel University College of Medicine where he served as chief resident and was named “Neurology Resident of the Year.” He performed his internal medicine residency at AtlantiCare Regional Medical Center. Dr. Gliebus earned his medical degree from Vilnius University in Lithuania, graduating magna cum laude.
Board-certified in neurology, Dr. Gliebus has a subspecialty certification in behavioral neurology and neuropsychiatry. As an attending physician and clinical leader to Drexel University medical students and neurology residents, Dr. Gliebus was honored with the Drexel University College of Medicine Dean’s Award for Excellence in Clinical Teaching.
Dr. Gliebus is a member of the American Academy of Neurology, the Society for Behavioral and Cognitive Neurology and the International Society to Advance Alzheimer Research and Treatment. He has presented his work at regional and national conferences, and his research has been published in medical journals such as the American Journal of Alzheimer's Disease & Other Dementias, Neurology and the Journal of Neuroscience.
Dr. Gliebus is currently a reviewer for the American Journal of Alzheimer's Disease and Other Dementias and Alzheimer’s and Dementia. He serves as a Scientific Advisory Board member for the National CADASIL Association. He also served as a board member of the New Jersey Brain Injury Alliance.
Dr. Gliebus is the recipient of three grants from the Drexel University Clinical and Translational Research Institute. He is also the principal investigator for a clinical trial evaluating the safety and efficacy of the drug MK-8931 for patients with Alzheimer's disease, as well as for several other trials.
To make an appointment with Dr. Gliebus, please call 856-470-9029 or visit http://www.lourdesnet.org.